Deals
Deal activity by volume related to ESG increased by 205% year-on-year in 2023 in the pharmaceutical industry
Credit: Bert van Dijk/Getty images.
Powered by
Analysis of the key themes driving deal activity reveals that ESG accounted for 280 pharmaceutical deals between 2019 and 2023, worth a total value of $10,632m, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships.
The $884.8m private equity investment in Ergomed by Permira Advisers was the largest disclosed deal in 2023, while the $40m equity offering by Mendel Health was the largest disclosed deal in 2022.
In volume terms, ESG related deal activity increased by 205% year-on-year in 2023 and by 47% year-on-year in 2022.
Deal activity related to ESG in the global pharma industry in the last five years
Top deals related to ESG in the pharma industry in the last five years
Deal volume by deal type for ESG related deals in the pharma industry in the last five years
Licensing agreements accounted for the highest number of deals in the last five years, with 107 deals, followed by Partnership (55 deals) and Venture financing (37 deals).
Top financial advisors for ESG related deals by value in the pharma industry in the last five years
The top financial advisors supporting deals related to ESG in the pharma industry in the last five years in terms of value were J.P. Morgan Securities, Barclays, Citigroup Global Markets, PJT Partners, and Goldman Sachs Group.
Top legal advisors for ESG related deals by value in the pharma industry in the last five years
The top legal advisors supporting deals related to ESG in the pharma industry in the last five years in terms of value were Kirkland & Ellis, Clifford Chance, Cravath, Swaine & Moore, Paul, Weiss, Rifkind, Wharton & Garrison, and Ropes & Gray.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.
